<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Calcinosis cutis: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Calcinosis cutis: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Calcinosis cutis: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen H Fernandez, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Dana S Ward, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 30, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H878868953">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "calcinosis cutis" describes the deposition of insoluble calcium salts in the skin and subcutaneous tissue. There are five subtypes of calcinosis cutis (see
         <a class="medical medical_review" href="/z/d/html/13756.html" rel="external">
          "Calcinosis cutis: Etiology and patient evaluation", section on 'Subtypes'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dystrophic calcinosis cutis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metastatic calcinosis cutis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Idiopathic calcinosis cutis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Iatrogenic calcinosis cutis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Calciphylaxis
        </p>
        <p>
        </p>
        <p>
         The treatment of calcinosis cutis is often challenging, and the subtype influences the approach to treatment. Potential interventions include treatment for an underlying disease, medication to reduce calcium deposits or associated inflammation, and surgical removal of calcium deposits.
        </p>
        <p>
         The management of the various subtypes of calcinosis cutis will be reviewed here. The diagnosis and evaluation of patients with calcinosis cutis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13756.html" rel="external">
          "Calcinosis cutis: Etiology and patient evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H369141007">
         <span class="h1">
          DYSTROPHIC CALCINOSIS CUTIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dystrophic calcinosis cutis, the most common form of calcinosis cutis, results from local tissue injury. Dystrophic calcinosis cutis most frequently occurs in association with autoimmune connective tissue diseases (particularly systemic sclerosis and dermatomyositis); therefore, the treatment of this presentation will be reviewed here. Less common causes include lobular panniculitides, porphyria cutanea tarda, select genodermatoses, cutaneous neoplasms, traumatic injury, and parasitic infections. (See
         <a class="medical medical_review" href="/z/d/html/13756.html" rel="external">
          "Calcinosis cutis: Etiology and patient evaluation", section on 'Dystrophic calcinosis cutis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18257623">
         <span class="h2">
          Treatment principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of dystrophic calcinosis cutis associated with autoimmune connective tissue disease is often difficult. Therefore, for many patients, the primary goal of treatment is to minimize symptoms and alleviate functional limitations rather than the complete resolution of cutaneous calcification [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Management typically begins with consideration of two questions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is the underlying autoimmune connective tissue disease adequately treated?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Do the signs and symptoms of calcinosis cutis warrant treatment?
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1083878054">
         <span class="h2">
          Treatment of underlying disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Suppression of activity of the associated autoimmune disease is suggested based upon the theory that autoimmune disease-related tissue injury contributes to risk for cutaneous calcification  (
         <a class="graphic graphic_algorithm graphicRef135240" href="/z/d/graphic/135240.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H187416093">
         <span class="h2">
          Treatment of calcinosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of calcinosis cutis associated with autoimmune connective tissue diseases involves careful consideration of the need for treatment and the selection of an appropriate treatment regimen.
        </p>
        <p class="headingAnchor" id="H2619100903">
         <span class="h3">
          Approach
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Decision to treat
         </strong>
         – Consideration of the severity of the signs and symptoms of calcinosis cutis is important because the response to treatment is variable and unpredictable, and there is risk for treatment-related adverse effects. Clinical follow-up without intervention to reduce calcium deposits is a reasonable option for calcinosis cutis that is asymptomatic, nonprogressive, unassociated with internal involvement, and of minimal concern to the patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment selection
         </strong>
         – Once the decision is made to pursue treatment, the challenge is to determine the best initial treatment regimen. Although responses to a wide variety of therapies are documented in the literature, data are insufficient for determining the most effective treatment pathway. Patient-specific factors, such as comorbidities and tolerance for specific interventions, influence treatment selection.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Drug therapy
         </strong>
         – Pharmacologic options include drugs that influence calcium or phosphorus metabolism, reduce associated inflammation, or act through unclear mechanisms. Compared with larger calcium deposits, small calcium deposits may respond better to pharmacologic therapy [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Drug therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgery
         </strong>
         – Surgical removal of calcinosis may be useful for patients with discrete, symptomatic areas of calcinosis cutis as the primary treatment or as an adjunct to medical therapy. Although early reports documenting poor wound healing and sinus track formation led to the historical avoidance of surgical procedures for dystrophic calcinosis cutis, subsequent reports suggest that surgery can be effective for some patients. (See
         <a class="local">
          'Role of surgery'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of therapy
         </strong>
         – Patients who respond to systemic pharmacologic therapies for calcinosis cutis are often maintained on continuous or intermittent treatment for months to years in an attempt to reduce risk for recurrence of disease. The ideal duration of medical treatment for calcinosis cutis is unclear.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2964529530">
         <span class="h3">
          Drug therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Efficacy data for all therapies for calcinosis cutis are limited. Our preferred initial treatment for dystrophic calcinosis cutis associated with autoimmune connective tissue disease is topical or intralesional
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         based upon the limited data that suggest efficacy and relative safety of this intervention  (
         <a class="graphic graphic_algorithm graphicRef135240" href="/z/d/graphic/135240.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Topical or intralesional sodium thiosulfate'
         </a>
         below.)
        </p>
        <p>
         Systemic therapies, such as
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         , are an option for patients in whom the number or extent of lesions makes local therapy impractical and patients who do not respond to or cannot access topical or intralesional
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         . (See
         <a class="local">
          'Alternative drug therapies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H32625389">
         <span class="h4">
          Topical or intralesional sodium thiosulfate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          Sodium thiosulfate
         </a>
         , an industrial chemical used in the treatment of disorders such as cyanide poisoning, calciphylaxis, and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         toxicity, may be of benefit for calcinosis cutis. Improvement is thought to result from potent antioxidant and vasodilatory properties.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration and precautions
         </strong>
         – Treatment regimens for
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         vary. Topical and intralesional administration are the primary modes of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Topical treatment generally consists of twice-daily application of compounded 10 to 25%
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         to the affected areas [
         <a href="#rid4">
          4
         </a>
         ]. Use of higher concentrations has also been reported [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Generally, a partial response is seen within the first month or two of therapy, but several months of treatment may be necessary to achieve a complete response [
         <a href="#rid4">
          4
         </a>
         ]. Topical therapy may be most beneficial for very small lesions [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intralesional
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         (150 to 250 mg/mL) is generally administered to individual lesions every one to four weeks until resolution or cessation of improvement. A reasonable initial regimen consists of 150 mg/mL given monthly, with the option to increase the concentration and frequency based on patient tolerance and response [
         <a href="#rid6">
          6
         </a>
         ]. Improvement may be evident within one to four treatments [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Examples of reported adverse effects of topical or intralesional
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         therapy include skin irritation and pain [
         <a href="#rid4">
          4,7,9
         </a>
         ]. Local infection has also been reported with intralesional therapy, likely due to the development of ulceration in association with softening of calcifications [
         <a href="#rid7">
          7
         </a>
         ]. Adverse effects reported in a case series of three patients who received intravenous sodium thiosulfate therapy for calcinosis cutis include headache, nausea, weakness, fatigue, and central catheter line infections [
         <a href="#rid10">
          10
         </a>
         ]. Metabolic acidosis and other side effects of intravenous sodium thiosulfate are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">
          "Calciphylaxis (calcific uremic arteriolopathy)", section on 'Side effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Data on the efficacy of
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         are limited to case reports and case series [
         <a href="#rid4">
          4-6,9,11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a systematic review of the literature that identified 42 patients with calcinosis cutis (including 36 patients with dystrophic calcinosis cutis) treated with 10 or 25% topical
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         (or 20 or 25% sodium metabisulfate [which forms a metabolite of sodium thiosulfate in vivo]), 20 percent had a complete response, 58 percent had a partial response, and 22 percent had no response [
         <a href="#rid4">
          4
         </a>
         ]. Mean durations of treatment to achieve complete and partial responses were five and four months, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a subsequent, retrospective study of outcomes from topical, intralesional, or intravenous
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         in 80 lesions of calcinosis cutis, lesion size appeared to influence the response to topical therapy [
         <a href="#rid5">
          5
         </a>
         ]. Although twice-daily application of topical sodium thiosulfate serum compounded 50:50 with petrolatum or a bland emollient was associated with resolution of all 53 treated lesions &lt;0.2 cm in size, lower resolution rates occurred for larger lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reports of intralesional injection of
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         describe varying results [
         <a href="#rid5">
          5-7
         </a>
         ]. In the retrospective study mentioned above, intradermal injection of undiluted sodium thiosulfate (0.1 to 1 mL of sodium thiosulfate 250 mg/mL) administered every three weeks was associated with resolution of 13 of 13 lesions ≤2 cm in size and no response in three larger lesions [
         <a href="#rid5">
          5
         </a>
         ]. In contrast, in a study in which four patients received a total of three, once-monthly treatments with diluted sodium thiosulfate (0.1 mL/cm
         <sup>
          2
         </sup>
         of sodium thiosulfate 40 mg/mL) into one calcinosis cutis lesion and
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         injection into a second lesion (maximum lesion size 2x2 cm), only one patient had improvement in a sodium thiosulfate-treated lesion [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H34318700">
         <span class="h4">
          Alternative drug therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic therapies, including
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         , are alternative therapies for calcinosis cutis associated with autoimmune connective tissue disease  (
         <a class="graphic graphic_algorithm graphicRef135240" href="/z/d/graphic/135240.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H582421973">
         <span class="h5">
          Selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         is a common systemic treatment for dystrophic calcinosis cutis associated with autoimmune connective tissue disease [
         <a href="#rid13">
          13
         </a>
         ]. Diltiazem inhibits calcium influx in cells, which may support a role in decreasing dystrophic calcification.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          Colchicine
         </a>
         or
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         is generally preferred over
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         for patients presenting with prominent inflammation or ulceration. Inflammation contributes significantly to the morbidity associated with calcinosis cutis, and limited data suggest the anti-inflammatory effects of these drugs may improve associated symptoms or ulceration [
         <a href="#rid2">
          2,14,15
         </a>
         ]. Varying degrees of improvement in calcium deposits have also been reported in some patients.
        </p>
        <p class="headingAnchor" id="H2640591">
         <span class="h5">
          Diltiazem
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration and precautions
         </strong>
         –
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         is prescribed most often at a dose of 2 to 4 mg/kg per day and has appeared to be of benefit for patients with dystrophic calcinosis associated with adult and juvenile dermatomyositis [
         <a href="#rid16">
          16-18
         </a>
         ], systemic sclerosis [
         <a href="#rid19">
          19
         </a>
         ], systemic lupus erythematosus [
         <a href="#rid20">
          20
         </a>
         ], lupus panniculitis [
         <a href="#rid21">
          21
         </a>
         ], and mixed connective tissue disease [
         <a href="#rid22">
          22
         </a>
         ]. Our typical dose for adults is 240 mg per day. Improvement may be evident within the first few months of treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Examples of adverse effects of
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         include edema, headache, atrioventricular block, bradycardia, hypotension, dizziness, and gastrointestinal symptoms. Risk for adverse effects of diltiazem may be greatest in patients with reduced ventricular function or cardiac conduction abnormalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Efficacy data for
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         are limited to case reports and case series, with conflicting conclusions on efficacy [
         <a href="#rid13">
          13
         </a>
         ]. A 2014 review of published cases found benefit of diltiazem documented in slightly more than one-half of reported cases [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Support for the drug stems from a retrospective study of patients with calcinosis cutis associated with autoimmune connective tissue disease in which 17 patients were given
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         (≤480 mg per day) [
         <a href="#rid1">
          1
         </a>
         ]. Of the 17 patients, 9 had a partial response to diltiazem, 3 had insufficient documentation of the outcome, and the remainder did not respond to therapy. A lower rate of response (as assessed with radiologic examination) was documented in a separate series of adults treated with diltiazem 180 mg per day for subcutaneous calcinosis cutis associated with systemic sclerosis [
         <a href="#rid23">
          23
         </a>
         ]. Slight improvement was evident in only 3 of 12 patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are fewer data on the efficacy of other calcium channel blockers for calcinosis cutis associated with autoimmune connective tissue disease. Partial improvement during
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         therapy has been reported in at least one patient [
         <a href="#rid1">
          1
         </a>
         ].
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         (120 mg per day) failed to yield improvement in another patient [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H367008729">
         <span class="h5">
          Colchicine
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration and precautions
         </strong>
         – Dosing of
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         for calcinosis cutis is not standardized; our typical regimen for adults is 0.6 mg twice daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A clinical response to
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         may be evident within a few months. Gastrointestinal distress is a common side effect of colchicine that can limit use in some patients. (See
         <a class="drug drug_general" href="/z/d/drug information/9293.html" rel="external">
          "Colchicine: Drug information"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Case reports document both treatment success and failure of
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         for calcinosis cutis [
         <a href="#rid13">
          13
         </a>
         ]. As examples, improvement in inflammation and healing of ulcerations secondary to calcinosis cutis occurred within two months of the start of colchicine (1 mg per day) in a child with systemic sclerosis as well as a child with dermatomyositis [
         <a href="#rid25">
          25
         </a>
         ]. In a separate retrospective study of patients with calcinosis cutis associated with autoimmune connective tissue disease, one of eight patients treated with colchicine (≤1.2 g per day) achieved complete resolution of calcinosis, and two patients achieved a partial response [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H367008736">
         <span class="h5">
          Minocycline
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration and precautions
         </strong>
         – Doses of
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         for calcinosis cutis range from 50 to 200 mg per day [
         <a href="#rid26">
          26
         </a>
         ]. Our typical regimen for adults is 100 mg twice daily. Minocycline should not be used for children under the age of nine years because of a potential for permanent tooth discoloration with long-term treatment. Responses may occur within the first several months of treatment [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to blue-black discoloration of calcium deposits, other potential side effects of
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         therapy include dizziness, skin discoloration, a hypersensitivity syndrome, and a lupus-like syndrome. (See
         <a class="drug drug_general" href="/z/d/drug information/122965.html" rel="external">
          "Minocycline (systemic): Drug information"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In an open-label study in which nine adult female patients with limited cutaneous systemic sclerosis were treated with
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         (50 or 100 mg per day), improvement primarily occurring as reduced inflammation or ulceration was noted in eight [
         <a href="#rid14">
          14
         </a>
         ]. More modest reductions in calcium deposits were also detected. Most patients exhibited improvement within several months, and improvement was noted within one month in two patients. Of note, blue-black discoloration of the calcium deposits occurred as a side effect of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         was also reviewed in a retrospective study that included six patients with calcinosis cutis associated with autoimmune connective tissue disease treated with minocycline (≤200 mg per day) [
         <a href="#rid1">
          1
         </a>
         ]. One patient achieved a partial response, two patients failed to respond, and the response to treatment was unknown for three patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18258859">
         <span class="h5">
          Other drug therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple other treatments have been used for dystrophic calcinosis cutis. Like
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         , these treatments have limited or conflicting efficacy data. Examples include
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         [
         <a href="#rid27">
          27
         </a>
         ], bisphosphonates [
         <a href="#rid28">
          28-31
         </a>
         ], intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         [
         <a href="#rid32">
          32-34
         </a>
         ], oral
         <a class="drug drug_general" data-topicid="8499" href="/z/d/drug information/8499.html" rel="external">
          aluminum hydroxide
         </a>
         [
         <a href="#rid2">
          2
         </a>
         ], intralesional corticosteroids [
         <a href="#rid35">
          35
         </a>
         ],
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         [
         <a href="#rid36">
          36
         </a>
         ],
         <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">
          probenecid
         </a>
         [
         <a href="#rid37">
          37
         </a>
         ],
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         [
         <a href="#rid38">
          38
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Intravenous
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         therapy is documented in case reports, with varying responses to therapy [
         <a href="#rid5">
          5,10,39,40
         </a>
         ]. The limited and conflicting efficacy data preclude a recommendation for the routine use of this therapy.
        </p>
        <p class="headingAnchor" id="H3594494478">
         <span class="h3">
          Role of surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgery is an additional primary or adjunctive treatment option for discrete, symptomatic areas of calcinosis cutis  (
         <a class="graphic graphic_algorithm graphicRef135240" href="/z/d/graphic/135240.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Surgical procedures may yield pain relief and improvement in functional limitations [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Data on surgical therapy are primarily limited to small case series and case reports. Surgical procedures that have been beneficial include surgical excision [
         <a href="#rid42">
          42
         </a>
         ], surgical excision with local fasciocutaneous flap [
         <a href="#rid3">
          3
         </a>
         ], debulking with a high-speed burr [
         <a href="#rid43">
          43
         </a>
         ], incision and drainage [
         <a href="#rid44">
          44
         </a>
         ], and carbon dioxide (CO
         <sub>
          2
         </sub>
         ) laser vaporization [
         <a href="#rid45">
          45
         </a>
         ]. Risks of surgical intervention include recurrence, poor wound healing, infection, and sinus formation [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18259083">
         <span class="h1">
          METASTATIC CALCINOSIS CUTIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metastatic calcinosis cutis results from an underlying defect in the metabolism of calcium or phosphorus, leading to precipitation of calcium in cutaneous or subcutaneous tissues and other sites. The most common cause of metabolic calcinosis cutis is chronic renal failure.
        </p>
        <p>
         Because the underlying defect is the cause of metastatic calcinosis cutis, treatment focuses on correcting the calcium phosphate product [
         <a href="#rid46">
          46
         </a>
         ]. The management of mineral disorders in chronic kidney disease is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">
          "Overview of the management of chronic kidney disease in adults", section on 'Mineral and bone disorders (MBD)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6092.html" rel="external">
          "Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18259090">
         <span class="h1">
          IDIOPATHIC CALCINOSIS CUTIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Idiopathic calcinosis cutis consists of a group of disorders in which calcium deposition occurs in the skin in the absence of tissue injury or a metabolic disorder. Examples include idiopathic calcification of the scrotum, subepidermal calcified nodule, and tumoral calcinosis. (See
         <a class="medical medical_review" href="/z/d/html/13756.html" rel="external">
          "Calcinosis cutis: Etiology and patient evaluation", section on 'Idiopathic calcinosis cutis'
         </a>
         .)
        </p>
        <p>
         Treatment of idiopathic calcinosis cutis is not necessary in asymptomatic patients who are not bothered by the condition. If treatment is desired, surgical excision is the treatment of choice. Of note, subepidermal calcified nodules often spontaneously resolve when the nodule ulcerates and eliminates calcium transepidermally.
        </p>
        <p class="headingAnchor" id="H18259097">
         <span class="h1">
          IATROGENIC CALCINOSIS CUTIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iatrogenic calcinosis most frequently results from extravasation of intravenous
         <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">
          calcium gluconate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">
          calcium chloride
         </a>
         , or phosphate-containing solutions into the skin. Observation without intervention is a reasonable initial approach for asymptomatic lesions because of the potential for spontaneous resolution within six months [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
         Treatments for dystrophic calcinosis cutis may be attempted for symptomatic iatrogenic calcinosis cutis; however, data confirming the efficacy of these interventions are lacking. Topical
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         therapy has been suggested based upon case reports that describe resolution of new-onset iatrogenic calcinosis cutis within four to six months during treatment with 10 or 25% topical sodium thiosulfate [
         <a href="#rid49">
          49-51
         </a>
         ]. (See
         <a class="local">
          'Topical or intralesional sodium thiosulfate'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H18259104">
         <span class="h1">
          CALCIPHYLAXIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Calciphylaxis is a life-threatening, calcific vasculopathy that can affect skin, subcutaneous tissue, and internal organs. The disorder usually occurs in the setting of end-stage kidney disease. Treatment of calciphylaxis is difficult, and many patients die within a few months of diagnosis. Infection of ulcerated areas leading to sepsis is a common cause of mortality. (See
         <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">
          "Calciphylaxis (calcific uremic arteriolopathy)"
         </a>
         .)
        </p>
        <p>
         The treatment of patients with calciphylaxis requires a multi-interventional approach that includes wound care, pain control, prompt treatment of infection, correction of abnormalities in plasma calcium and phosphorus concentrations, avoidance of local tissue trauma, and other interventions. The treatment of calciphylaxis is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">
          "Calciphylaxis (calcific uremic arteriolopathy)", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">
          "Calciphylaxis (calcific uremic arteriolopathy)", section on 'Prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H367009126">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Calcinosis cutis is a disorder characterized by the deposition of insoluble calcium salts in the skin or subcutaneous tissue. There are five subtypes of calcinosis cutis: dystrophic, metastatic, idiopathic, iatrogenic, and calciphylaxis. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dystrophic calcinosis cutis
         </strong>
         – Dystrophic calcinosis cutis most often occurs in association with autoimmune connective tissue disease. Treatment of this presentation consists of suppression of the associated autoimmune disease and interventions to improve lesions of calcinosis cutis and associated symptoms  (
         <a class="graphic graphic_algorithm graphicRef135240" href="/z/d/graphic/135240.html" rel="external">
          algorithm 1
         </a>
         ). Data on therapies for dystrophic calcinosis cutis are limited, leading to uncertainty about the best approach to the management of this disease. (See
         <a class="local">
          'Dystrophic calcinosis cutis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Whom to treat
         </strong>
         – Not all patients require treatment beyond suppression of the associated autoimmune disease. Clinical follow-up without intervention to reduce calcium deposits is a reasonable option for calcinosis cutis that is asymptomatic, nonprogressive, unassociated with internal involvement, and of minimal concern to the patient. (See
         <a class="local">
          'Treatment principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients proceeding with treatment
         </strong>
         – For patients with autoimmune connective tissue disease-associated dystrophic calcinosis that is symptomatic, progressive, or of other concern to the patient, we suggest topical or intralesional
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         as initial treatment rather than systemic therapy  (
         <a class="graphic graphic_algorithm graphicRef135240" href="/z/d/graphic/135240.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Topical or intralesional sodium thiosulfate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Systemic treatment with
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         is an alternative for patients in whom the number or extent of lesions makes local therapy impractical and patients who do not respond to or cannot access topical or intralesional
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         . Surgical removal is an additional option for discrete, symptomatic areas of calcinosis cutis  (
         <a class="graphic graphic_algorithm graphicRef135240" href="/z/d/graphic/135240.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Alternative drug therapies'
         </a>
         above and
         <a class="local">
          'Role of surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metastatic calcinosis cutis
         </strong>
         – Metastatic calcinosis cutis primarily occurs in the setting of chronic renal disease. The management of these patients focuses on treatment of the underlying defect in the metabolism of calcium or phosphorus. (See
         <a class="local">
          'Metastatic calcinosis cutis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Idiopathic calcinosis cutis
         </strong>
         – Idiopathic calcification of the scrotum, subepidermal calcified nodule, and tumoral calcinosis are forms of idiopathic calcinosis cutis. If treatment is desired, the calcium deposits can be removed with surgical excision. (See
         <a class="local">
          'Idiopathic calcinosis cutis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Iatrogenic calcinosis cutis
         </strong>
         – Iatrogenic calcinosis cutis most often results from extravasation of intravenous
         <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">
          calcium gluconate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">
          calcium chloride
         </a>
         , or phosphate-containing solutions into the skin. Iatrogenic calcinosis cutis often resolves spontaneously over the course of several months. (See
         <a class="local">
          'Iatrogenic calcinosis cutis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calciphylaxis
         </strong>
         – Calciphylaxis is a life-threatening, calcific vasculopathy that usually occurs in the setting of end-stage kidney disease. Management consists of a multi-interventional approach involving wound care, pain control, prompt treatment of infection, correction of abnormalities in plasma calcium and phosphorus concentrations, avoidance of local tissue trauma, and other interventions. (See
         <a class="local">
          'Calciphylaxis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">
          "Calciphylaxis (calcific uremic arteriolopathy)", section on 'Treatment'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol 2012; 148:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin Arthritis Rheum 2005; 34:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welborn MC, Gottschalk H, Bindra R. Juvenile Dermatomyositis: A Case of Calcinosis Cutis of the Elbow and Review of the Literature. J Pediatr Orthop 2015; 35:e43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricardo JW, Sun HY, Gorji M, Sebaratnam DF. Topical sodium thiosulfate as treatment of calcinosis cutis: Case series and systematic review. J Am Acad Dermatol 2022; 87:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard RM, Smith GP. Treatment of calcinosis cutis with sodium thiosulfate therapy. J Am Acad Dermatol 2020; 83:1518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Sundh AE, Quintana-Sancho A, Durán-Vian C, et al. Clinical and ultrasound response to intralesional sodium thiosulfate for the treatment of calcinosis cutis in the setting of systemic sclerosis. A case-based review. Clin Rheumatol 2021; 40:2985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumgartner-Nielsen J, Olesen AB. Treatment of Skin Calcifications with Intra-lesional Injection of Sodium Thiosulphate: A Case Series. Acta Derm Venereol 2016; 96:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunasekera NS, Maniar LEG, Lezcano C, et al. Intralesional Sodium Thiosulfate Treatment for Calcinosis Cutis in the Setting of Lupus Panniculitis. JAMA Dermatol 2017; 153:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma JE, Ernste FC, Davis MDP, Wetter DA. Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017. Clin Exp Dermatol 2019; 44:e189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song P, Fett NM, Lin J, et al. Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis. Br J Dermatol 2018; 178:1412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Hodenberg C, Neufeld M, Wohlrab J, et al. Topical sodium thiosulfate: a reliable treatment for digital calcinosis cutis - a case series with six patients. J Dtsch Dermatol Ges 2020; 18:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winter AR, Klager S, Truong R, et al. Efficacy of intralesional sodium thiosulfate for the treatment of dystrophic calcinosis cutis: A double-blind, placebo-controlled pilot study. JAAD Int 2020; 1:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dima A, Balanescu P, Baicus C. Pharmacological treatment in calcinosis cutis associated with connective-tissue diseases. Rom J Intern Med 2014; 52:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson LP, Marshall RW, Hickling P. Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 2003; 62:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taborn J, Bole GG, Thompson GR. Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis. Ann Intern Med 1978; 89:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ichiki Y, Akiyama T, Shimozawa N, et al. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol 2001; 144:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinen CS, Patel S, Bruckner FE. Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy. Rheumatology (Oxford) 2000; 39:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torralba TP, Li-Yu J, Navarra ST. Successful use of diltiazem in calcinosis caused by connective tissue disease. J Clin Rheumatol 1999; 5:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiter N, El-Shabrawi L, Leinweber B, et al. Calcinosis cutis: part I. Diagnostic pathway. J Am Acad Dermatol 2011; 65:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dönmez O, Durmaz O. Calcinosis cutis universalis with pediatric systemic lupus erythematosus. Pediatr Nephrol 2010; 25:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan KW, Callen JP. Calcifying lupus panniculitis in a patient with subacute cutaneous lupus erythematosus: response to diltiazem and chloroquine. J Rheumatol 2001; 28:2129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goolamali SI, Gordon P, Salisbury J, Creamer D. Subcutaneous calcification presenting in a patient with mixed connective tissue disease and cutaneous polyarteritis nodosa. Clin Exp Dermatol 2009; 34:e141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vayssairat M, Hidouche D, Abdoucheli-Baudot N, Gaitz JP. Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? Ann Rheum Dis 1998; 57:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmieri GM, Sebes JI, Aelion JA, et al. Treatment of calcinosis with diltiazem. Arthritis Rheum 1995; 38:1646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs D, Fruchter L, Fishel B, et al. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol 1986; 5:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traineau H, Aggarwal R, Monfort JB, et al. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. J Am Acad Dermatol 2020; 82:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cukierman T, Elinav E, Korem M, Chajek-Shaul T. Low dose warfarin treatment for calcinosis in patients with systemic sclerosis. Ann Rheum Dis 2004; 63:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palaniappan P, Lionel AP, Kumar S. Successful treatment of calcinosis cutis in juvenile dermatomyositis with pamidronate. J Clin Rheumatol 2014; 20:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 2010; 77:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 2001; 138:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terroso G, Bernardes M, Aleixo A, et al. Therapy of calcinosis universalis complicating adult dermatomyositis. Acta Reumatol Port 2013; 38:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schanz S, Ulmer A, Fierlbeck G. Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol 2008; 144:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalajian AH, Perryman JH, Callen JP. Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands. Arch Dermatol 2009; 145:334; author reply 335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galimberti F, Li Y, Fernandez AP. Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis. J Am Acad Dermatol 2015; 73:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazen PG, Walker AE, Carney JF, Stewart JJ. Cutaneous calcinosis of scleroderma. Successful treatment with intralesional adrenal steroids. Arch Dermatol 1982; 118:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiter N, El-Shabrawi L, Leinweber B, Aberer E. Subcutaneous morphea with dystrophic calcification with response to ceftriaxone treatment. J Am Acad Dermatol 2010; 63:e53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eddy MC, Leelawattana R, McAlister WH, Whyte MP. Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy. J Clin Endocrinol Metab 1997; 82:3536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badawi AH, Patel V, Warner AE, Hall JC. Dystrophic calcinosis cutis: treatment with intravenous sodium thiosulfate. Cutis 2020; 106:E15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mageau A, Guigonis V, Ratzimbasafy V, et al. Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: Report of four cases. Joint Bone Spine 2017; 84:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 2005; 32:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendelson BC, Linscheid RL, Dobyns JH, Muller SA. Surgical treatment of calcinosis cutis in the upper extremity. J Hand Surg Am 1977; 2:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapner MA, Goetz TJ. High-speed burr debulking of digital calcinosis cutis in scleroderma patients. J Hand Surg Am 2014; 39:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu JJ, Metz BJ. Calcinosis cutis of juvenile dermatomyositis treated with incision and drainage. Dermatol Surg 2008; 34:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamberlain AJ, Walker NP. Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol Surg 2003; 29:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan O, Atik B, Kizilkaya A, et al. Extensive skin calcifications in an infant with chronic renal failure: metastatic calcinosis cutis. Pediatr Dermatol 2006; 23:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonohata M, Akiyama T, Fujita I, et al. Neonate with calcinosis cutis following extravasation of calcium gluconate. J Orthop Sci 2008; 13:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss J, Syrengelas A, Antaya R, Lazova R. Calcinosis cutis: a complication of intravenous administration of calcium glucanate. J Cutan Pathol 2006; 33 Suppl 2:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-García E, López-López R, Álvarez-Del-Vayo C, Bernabeu-Wittel J. Iatrogenic Calcinosis Cutis Successfully Treated with Topical Sodium Thiosulfate. Pediatr Dermatol 2017; 34:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott J, Kowalski EH, Klein S, et al. Iatrogenic calcinosis cutis secondary to calcium chloride successfully treated with topical sodium thiosulfate. JAAD Case Rep 2020; 6:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie CB, Kidacki M, Ring N, et al. Iatrogenic calcinosis cutis from extravasated phosphate-containing solution treated with topical sodium thiosulfate. JAAD Case Rep 2021; 17:31.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 100751 Version 10.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22184719" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15942915" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Calcinosis in rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25412072" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Juvenile Dermatomyositis: A Case of Calcinosis Cutis of the Elbow and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34537249" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Topical sodium thiosulfate as treatment of calcinosis cutis: Case series and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32622148" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment of calcinosis cutis with sodium thiosulfate therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33244722" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical and ultrasound response to intralesional sodium thiosulfate for the treatment of calcinosis cutis in the setting of systemic sclerosis. A case-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26258586" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Treatment of Skin Calcifications with Intra-lesional Injection of Sodium Thiosulphate: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28564698" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Intralesional Sodium Thiosulfate Treatment for Calcinosis Cutis in the Setting of Lupus Panniculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30251264" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28667747" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32743917" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Topical sodium thiosulfate: a reliable treatment for digital calcinosis cutis - a case series with six patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34409331" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Efficacy of intralesional sodium thiosulfate for the treatment of dystrophic calcinosis cutis: A double-blind, placebo-controlled pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25338341" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pharmacological treatment in calcinosis cutis associated with connective-tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12594118" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/717938" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11298557" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10788545" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19078360" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Successful use of diltiazem in calcinosis caused by connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21679810" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Calcinosis cutis: part I. Diagnostic pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20130918" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Calcinosis cutis universalis with pediatric systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11550987" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Calcifying lupus panniculitis in a patient with subacute cutaneous lupus erythematosus: response to diltiazem and chloroquine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19508582" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Subcutaneous calcification presenting in a patient with mixed connective tissue disease and cutaneous polyarteritis nodosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9709184" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7488286" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Treatment of calcinosis with diltiazem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3816102" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31302187" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15361398" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Low dose warfarin treatment for calcinosis in patients with systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25417690" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Successful treatment of calcinosis cutis in juvenile dermatomyositis with pamidronate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20031471" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11343059" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24131911" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Therapy of calcinosis universalis complicating adult dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18490584" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Response of dystrophic calcification to intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19289776" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26089058" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7082035" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Cutaneous calcinosis of scleroderma. Successful treatment with intralesional adrenal steroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20633791" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Subcutaneous morphea with dystrophic calcification with response to ceftriaxone treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9360503" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18403404" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32941566" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Dystrophic calcinosis cutis: treatment with intravenous sodium thiosulfate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27955821" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: Report of four cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15801019" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Surgery of the hand in patients with systemic sclerosis: outcomes and considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/556475" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Surgical treatment of calcinosis cutis in the upper extremity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24559627" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : High-speed burr debulking of digital calcinosis cutis in scleroderma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18248486" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Calcinosis cutis of juvenile dermatomyositis treated with incision and drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12930342" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16780469" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Extensive skin calcifications in an infant with chronic renal failure: metastatic calcinosis cutis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18528663" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Neonate with calcinosis cutis following extravasation of calcium gluconate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16972958" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Calcinosis cutis: a complication of intravenous administration of calcium glucanate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28382733" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Iatrogenic Calcinosis Cutis Successfully Treated with Topical Sodium Thiosulfate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32149171" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Iatrogenic calcinosis cutis secondary to calcium chloride successfully treated with topical sodium thiosulfate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34692964" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Iatrogenic calcinosis cutis from extravasated phosphate-containing solution treated with topical sodium thiosulfate.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
